Physician profile
Anca Goller
NPI 1083765036
$1,112.57
in general payments reported to CMS, 2019-2025
20 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $122 · 2022: $118 · 2023: $138 · 2024: $88.99 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $144.23 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $133.25 | 2019-2025 | Mounjaro, Zepbound, Baqsimi |
| Novo Nordisk INC | $125.07 | 2019-2023 | Rybelsus, Ozempic |
| Abbott Laboratories | $96.37 | 2022-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $64.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $58.23 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $56.69 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $47.44 | 2024-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $43.25 | 2019-2020 | |
| Insulet Corporation | $41.11 | 2024-2025 | Omnipod |
| Aytu Biopharma, INC. | $40.80 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $40.11 | 2025 | Recorlev |
| Dexcom, INC. | $35.86 | 2020-2023 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $34.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.73 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $29.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.57 | 2020 | |
| Abbvie INC. | $24.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.36 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anca Goller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.